US drugmaker Forest Laboratories (NYSE: FRX) and Janssen Pharmaceutica, a unit of health care giant Johnson & Johnson (NYSE: JNJ), have jointly filed a law suit in the US District Court for the District of Delaware against several companies for infringement of the US patent relating to their antihypertensive Bystolic (nebivol), which they say expires in December 2021, including patent term extension.
The defendants named in the law suit include Amerigen Pharmaceuticals, Glenmark Generics, Hetero USA, Torrent Pharmaceuticals, Watson Laboratories and related companies and subsidiaries. Forest and Janssen (which licensed Bystolic to Forest) also filed a law suit in the US District Court for the Northern District of Illinois against Alkem Laboratories and Indchemie Health Specialties for infringement of the patent.
Watson confirms ANDA filing
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze